Many patients who contract COVID-19 have detectable lung dysfunction 12 weeks after hospital discharge, results have suggested.
Addition of baricitinib to mainstay of treatment improves signs and symptoms of atopic dermatitis, study findsSubscription
Adding the oral selective Janus kinase 1 and 2 inhibitor, baricitinib, to topical corticosteroid treatment significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis, a phase III study in JAMA Dermatology has suggested.
Prescribing asthma treatment based on genetic differences could improve outcomes, results presented at the European Respiratory Society International Congress have suggested.
Gaps between clinical guidelines and practice for lipid management in Europe, researchers findSubscription
Less than 60% of patients receiving lipid-lowering therapy achieve the low-density lipoprotein cholesterol levels set out in European guidelines.
Honey is superior to usual care for improving symptoms of upper respiratory tract infection symptoms, researchers have concluded.
Novel once-daily fixed-dose ICS–LABA improves lung function over ICS monotherapy, research findsSubscription
A once-daily fixed-dose combination of inhaled corticosteroids and long-acting β2-adrenoceptor agonist significantly improved lung function over inhaled corticosteroids alone, a phase III study has concluded.
Abrocitinib, an oral Janus kinase 1 selective inhibitor, is effective and well-tolerated in patients with moderate-to-severe atopic dermatitis, a study in JAMA Dermatology has suggested.
A daily prescribing round in a paediatric intensive care unit led to a reduction in prescribing errors and overall time spent on medicines queries and prescribing.